Found: 7
Select item for more details and to access through your institution.
Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
- Published in:
- Scientific Reports, 2016, p. 36182, doi. 10.1038/srep36182
- By:
- Publication type:
- Article
Long‐term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
- Published in:
- Journal of Inherited Metabolic Disease, 2020, v. 43, n. 6, p. 1219, doi. 10.1002/jimd.12272
- By:
- Publication type:
- Article
Late‐onset Pompe disease in France: molecular features and epidemiology from a nationwide study.
- Published in:
- Journal of Inherited Metabolic Disease, 2018, v. 41, n. 6, p. 937, doi. 10.1007/s10545-018-0243-7
- By:
- Publication type:
- Article
Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.
- Published in:
- Journal of Inherited Metabolic Disease, 2018, v. 41, n. 6, p. 937, doi. 10.1007/s10545-018-0243-7
- By:
- Publication type:
- Article
Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.
- Published in:
- European Journal of Neurology, 2024, v. 31, n. 7, p. 1, doi. 10.1111/ene.16292
- By:
- Publication type:
- Article
Macroglossia: A potentially severe complication of late‐onset Pompe disease.
- Published in:
- European Journal of Neurology, 2022, v. 29, n. 7, p. 2121, doi. 10.1111/ene.15330
- By:
- Publication type:
- Article
Motor and respiratory decline in patients with late onset Pompe disease after cessation of enzyme replacement therapy during COVID‐19 pandemic.
- Published in:
- European Journal of Neurology, 2022, v. 29, n. 4, p. 1181, doi. 10.1111/ene.15222
- By:
- Publication type:
- Article